Pharma Mar SAU (PHMR)

Real-time derived
Currency in EUR
81.000
-0.550(-0.67%)
Closed·
PHMR Scorecard
Full Analysis
Impressive gross profit margins
PHMR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
80.15081.900
52 wk Range
31.820105.800
Key Statistics
Edit
Prev. Close
81.05
Open
81
Day's Range
80.15-81.9
52 wk Range
31.82-105.8
Volume
31.45K
Average Volume (3m)
64.42K
1-Year Change
134.92%
Book Value / Share
11.24
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PHMR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
100.000
Upside
+23.46%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple

Pharma Mar SAU News & Analysis

Show more

Pharma Mar SAU Company Profile

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.

Employees
500
Market
Spain

Compare PHMR to Peers and Sector

Metrics to compare
PHMR
Peers
Sector
Relationship
P/E Ratio
72.1x3.1x−0.4x
PEG Ratio
-0.060.00
Price/Book
7.3x2.7x2.6x
Price / LTM Sales
8.2x6.7x3.0x
Upside (Analyst Target)
35.8%45.9%52.3%
Fair Value Upside
Unlock2.9%9.4%Unlock

Analyst Ratings

3 Buy
2 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 100.000
(+23.46% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS -
Dividend Yield
0.98%
Industry Median 0.81%
Annualised payout
0.80
Paid unevenly
5-Years Growth
+10.76%
Growth Streak

Earnings

Latest Release
Apr 24, 2025
EPS / Forecast
-0.11 / 0.63
Revenue / Forecast
38.90M / 42.70M
EPS Revisions
Last 90 days

People Also Watch

19.570
TRE
-0.41%
5.330
A3M
-0.37%
11.085
BKT
-1.34%
35.740
IDR
-0.39%
146.500
ANA
-0.95%

FAQ

What Is the Pharma Mar SAU (PHMR) Stock Price Today?

The Pharma Mar SAU stock price today is 81.00

What Stock Exchange Does Pharma Mar SAU Trade On?

Pharma Mar SAU is listed and trades on the Madrid Stock Exchange stock exchange.

What Is the Stock Symbol for Pharma Mar SAU?

The stock symbol for Pharma Mar SAU is "PHMR."

Does Pharma Mar SAU Pay Dividends? What’s The Current Dividend Yield?

The Pharma Mar SAU dividend yield is 0.99%.

What Is the Pharma Mar SAU Market Cap?

As of today, Pharma Mar SAU market cap is 1.42B.

What Is Pharma Mar SAU's Earnings Per Share (TTM)?

The Pharma Mar SAU EPS (TTM) is 0.00.

When Is the Next Pharma Mar SAU Earnings Date?

Pharma Mar SAU will release its next earnings report on 23 Jul 2025.

From a Technical Analysis Perspective, Is PHMR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Pharma Mar SAU Stock Split?

Pharma Mar SAU has split 1 times.

How Many Employees Does Pharma Mar SAU Have?

Pharma Mar SAU has 500 employees.

What is the current trading status of Pharma Mar SAU (PHMR)?

As of 18 Jun 2025, Pharma Mar SAU (PHMR) is trading at a price of 81.00, with a previous close of 81.05. The stock has fluctuated within a day range of 80.15 to 81.90, while its 52-week range spans from 31.82 to 105.80.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.